83 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

1. Shirley M, et al. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs 2014; 74:1097–1110.
2. US Food and Drug Administration. Highlights of Prescribing Information. Abilify Maintena (aripiprazole) for extended-­release suspension for intramuscular use. 2020 (last accessed August 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202971s013lbl.pdf.
3. Raoufinia A, et al. Initiation of aripiprazole once-­monthly in patients with schizophrenia. Curr Med Res Opin 2015; 31:583–592.
4. Otsuka Pharmaceuticals (UK) Ltd. Summary of Product Characteristics. Abilify Maintena 400 mg powder and solvent for prolonged-­release suspension for injection. 2024 (last accessed October 2024); https://www.medicines.org.uk/emc/product/7965/smpc.
5. Raoufinia A, et al. Aripiprazole once-­monthly 400 mg: comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration. Int J Neuropsychopharmacol 2017; 20:295–304.
6. Mallikaarjun S, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-­monthly in adult schizophrenia: an open-­label, parallel-­ arm, multiple-­dose study. Schizophr Res 2013; 150:281–288.
7. Otsuka Pharmaceutical Co Ltd. Highlights of Prescribing Information. ABILIFY MAINTENA® (aripiprazole) for extended-­release injectable suspension, for intramuscular use. 2017 (last accessed October 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/ 202971s013lbl.pdf.
8. Otsuka Pharmaceuticals (UK) Ltd. Summary of Product Characteristics. Abilify Maintena 960 mg prolonged-­release suspension for injection in pre-­filled syringe. 2024 (last accessed October 2024); https://www.medicines.org.uk/emc/product/15679/smpc.
9. Otsuka Pharmaceutical Co Ltd. Highlights of Prescribing Information. ABILIFY ASIMTUFII® (aripiprazole) extended-­release injectable ­suspension for intramuscular use. 2023 (last accessed October 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/ 217006s000lbl.pdf.
10. Citrome L, et al. Safety and efficacy of aripiprazole 2-­month ready-­to-­use 960 mg: secondary analysis of outcomes in adult patients with schizophrenia in a randomized, open-­label, parallel-­arm, pivotal study. J Clin Psychiatry 2023; 84:23m14873.
11. Harlin M, et al. A randomized, open-­label, multiple-­dose, parallel-­arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-­month long-­acting injectable in adults with schizophrenia or bipolar I disorder. CNS Drugs 2023; 37:337–350.
12. McIntyre RS, et al. Safety and efficacy of aripiprazole 2-­month ready-­to-­use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-­label, parallel-­arm, pivotal study. Curr Med Res Opin 2023; 39:1021–1030.
13. Samalin L, et al. Evaluating the efficacy and safety of the currently available once-­every-­two months long-­acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults. Expert Rev Neurother 2024; 24:291–298.
14. Alkermes Inc. ARISTADA INITIO™ (aripiprazole lauroxil) extended-­release injectable suspension [product monograph]. 2020 (last accessed October 2024); https://www.aristadacaresupport.com/downloadables/ARISTADA-­INITIO-­ARISTADA-­Payer-­Hospital-­Monograph.pdf.
15. Hard ML, et al. Aripiprazole lauroxil: pharmacokinetic profile of this long-­acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol 2017; 37:289–295.
16. Turncliff R, et al. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-­monthly, long-­acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophr Res 2014; 159:404–410.
17. Alkermes Inc. Highlights of Prescribing Information. ARISTADA® (aripiprazole lauroxil) extended-­release injectable suspension for intramuscular use. 2018 (last accessed October 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207533s013lbl.pdf.
18. Citrome L, et al. Safety and tolerability of starting aripiprazole lauroxil with aripiprazole lauroxil nanocrystal dispersion in 1 day followed by aripiprazole lauroxil every 2 months using paliperidone palmitate monthly as an active control in patients with schizophrenia: a post hoc analysis of a randomized controlled trial. J Clin Psychiatry 2024; 85:23m15095.
19. Harlin M, et al. Aripiprazole plasma concentrations delivered from two 2-­month long-­acting injectable formulations: an indirect comparison. Neuropsychiatr Dis Treat 2023; 19:1409–1416.